Synopsis
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.
Episodes
-
![Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)]()
Late Stage Oropharynx Cancer, Chemotherapy - Options and Practice (audio)
16/04/2014 Duration: 16minDr. Jared Weiss, University of North Carolina, discusses chemotherapy options and practice in late stage oropharynx cancer.
-
![Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)]()
Late Stage Oropharynx Cancer, Treatment and Side Effects (audio)
30/03/2014 Duration: 15minDr. Geoffrey Geiger, University of Pennsylvania, outlines the course of radiotherapy treatment and side effects for head and neck cancer.
-
![Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)]()
Late Stage Oropharynx Cancer, Planning for External Beam Radiotherapy (audio)
30/03/2014 Duration: 14minDr. Geoffrey Geiger, University of Pennsylvania, discusses the process of planning radiotherapy for head and neck cancer.
-
![Late Stage Oropharynx Cancer, Introduction and Management (audio)]()
Late Stage Oropharynx Cancer, Introduction and Management (audio)
30/03/2014 Duration: 18minDr. Geoffrey Geiger, University of Pennsylvania, provides an introduction to head and neck cancer and the human papilloma virus.
-
![Squamous Lung Cancer Part 5, Q and A Session (audio)]()
Squamous Lung Cancer Part 5, Q and A Session (audio)
20/12/2013 Duration: 13minDr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
-
![Squamous Lung Cancer, Part 4: Immunotherapy (audio)]()
Squamous Lung Cancer, Part 4: Immunotherapy (audio)
10/12/2013 Duration: 07minDr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
-
![Squamous Lung Cancer, Part 3: Treatment (audio)]()
Squamous Lung Cancer, Part 3: Treatment (audio)
08/12/2013 Duration: 12minDr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
-
![Squamous Lung Cancer, Part 2: Genomic Testing (audio)]()
Squamous Lung Cancer, Part 2: Genomic Testing (audio)
06/12/2013 Duration: 11minDr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
-
![Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)]()
Squamous Lung Cancer, Part 1: Diagnosis, Presentation and Workup (audio)
02/12/2013 Duration: 15minDr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.
-
![Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)]()
Chemotherapy for Pancreatic Cancer, Part 6: Moving Forward in Advanced Pancreatic Cancer (audio)
28/09/2013 Duration: 06minDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews novel approaches, including nab-paclitaxel with gemcitabine, in advanced pancreatic cancer.
-
![Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)]()
Chemotherapy for Pancreatic Cancer, Part 5: Chemotherapy for Metastatic Pancreatic Cancer (audio)
28/09/2013 Duration: 08minDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, discusses the history of and recent developments in chemotherapy for metastatic pancreatic cancer.
-
![Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)]()
Chemotherapy for Pancreatic Cancer, Part 4: Post-Operative (Adjuvant) Treatment for Pancreatic Cancer (audio)
21/09/2013 Duration: 12minDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, covers the rationale and evidence for post-operative (adjuvant) therapy for resectable pancreatic cancer.
-
![Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)]()
Chemotherapy for Pancreatic Cancer, Part 3: Pre-Operative Treatment for Pancreatic Cancer (audio)
19/09/2013 Duration: 07minDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
-
![Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)]()
Chemotherapy for Pancreatic Cancer, Part 2: Resectable vs. Unresectable Pancreatic Cancer (audio)
09/09/2013 Duration: 05minDr. Colin Weekes, pancreatic cancer specialist from the University of Colorado, reviews the differentiation between resectable and unresectable pancreatic cancer.
-
![ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)]()
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (audio)
04/09/2013 Duration: 05minDr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
-
![ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)]()
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (audio)
31/08/2013 Duration: 05minDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.
-
![ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)]()
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (audio)
26/08/2013 Duration: 05minDr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.
-
![ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)]()
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (audio)
26/08/2013 Duration: 05minDr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
-
![ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)]()
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)
23/08/2013 Duration: 09minDr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.
-
![ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)]()
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (audio)
23/08/2013 Duration: 07minDr. Edward Garon, David Geffen School of Medicine at UCLA, reviews the landmark Biomarkers France study that tested a wide range of molecular markers in NSCLC.
